Gene Therapy for Genetic Diseases: What Sponsors Need to Know Before They Get to the IRB & IBC
Gene therapy holds promise for patients with genetic diseases, yet it also represents a fundamental departure from the paradigm most drug-development professionals were trained in. The therapeutic agents and patient populations are different, and the regulatory and ethical framework is unlike anything most sponsors have navigated before. Encountering these differences for the first time at the IRB or IBC submission stage can be costly.
The core tension is structural. Conventional drug development assumes a sequential safety model: you start in healthy adult volunteers, establish a tolerability profile, and expand from there. Gene therapy for genetic diseases does not fit that model.
The sponsors who succeed are the ones who understand what that demands before they submit anything.
Why Gene Therapy Requires a Different Safety Paradigm
Healthy volunteer studies are rarely an option when it comes to gene therapy trials. Animal models are frequently inadequate, particularly for rare monogenic diseases where no animal fully recapitulates the human condition. And when the target population is pediatric, the regulatory framework governing what you can ask those patients to undergo is substantially more restrictive than that for adults.
Federal regulations governing pediatric research draw a meaningful distinction based on the prospect of direct benefit. Procedures that carry more than minimal risk are generally not permissible for children who cannot potentially benefit from them directly. However, in many genetic diseases, patients do not survive to adulthood. That means the standard model of establishing safety in adults before moving to more vulnerable populations does not apply. There are no adults with the disease to study first.
Sponsors developing gene therapies for these conditions are working in pediatric populations from the outset, navigating a regulatory framework that treats that context with appropriate seriousness, and doing so with science that is still maturing. For sponsors, this imposes constraints on study design that are easy to underestimate. A protocol that works fine in an adult population may not be approvable as written when applied to children.
The consequences of getting this wrong are real. In 2017, Sarepta Therapeutics encountered significant delays in a Duchenne muscular dystrophy study after most IRBs declined to approve the protocol as written. The protocol allowed the placement of long-term IV access in children who were in the placebo group, a procedure carrying procedural and infection risk with no possibility of direct benefit for those patients. While the rationale to avoid frequent painful and frustrating peripheral IV infusions was completely reasonable, the regulations simply did not allow IRBs to approve the protocol as initially written. The issue required a special FDA advisory meeting before it could be resolved. The meeting minutes are publicly available and serve as a useful reminder that pediatric protocol design decisions have real downstream consequences for program timelines.
Beyond pediatric considerations, gene therapy introduces safety dimensions that are not present in conventional drug development. The viral vectors used to deliver gene therapies vary significantly in their risk profiles. Some are derived from naturally occurring viruses; some may be excreted by patients after dosing, creating biosafety considerations that extend beyond the patient to families, caregivers, and clinical staff. Those risks require a different oversight structure from that of a traditional Investigational New Drug application.
What Sponsors Need to Build Before Submitting to IRBs & IBCs
First-in-human gene therapy trials are almost always open-label and non-randomized. That design choice is often appropriate given the patient population and the nature of the intervention, but it means the safety oversight infrastructure has to do more work, not less. The absence of a control arm makes stopping rules, safety assessment committees, and formal review points at study inflection points even more important, not optional add-ons.
IRBs reviewing gene therapy protocols will evaluate whether the sponsor has given serious consideration to the specific risks associated with the therapeutic agent. That means the protocol and supporting documents should reflect a clear understanding of the viral vector, the biosafety category it falls under, the known and potential risks, and the sponsor’s plan to detect and respond to safety signals in real time. Stopping rules should be present where appropriate.
Long-term follow-up is another area where sponsors frequently arrive underprepared. FDA guidance specifies follow-up periods of up to 15 years for certain gene therapy products, depending on the vector and integration profile. Some sponsors address this within the primary protocol; others plan a separate protocol for the long-term follow-up phase. Either approach can work, but the plan (and the second protocol, if using this pathway) must exist before you submit to the IRB and must be consistent with the rest of the safety framework. IRBs cannot accept “we’ll write the follow-up protocol later” as evidence that the required follow-up will be completed.
The IBC plays a distinct but equally important role. While the IRB is responsible for protecting study participants, the IBC is responsible for protecting everyone else: laboratory personnel, clinical staff, and, in some cases, patient families who may be exposed to a viral vector post-dosing. Together, the IRB and IBC create a safety assessment framework that accounts for the full range of people who may be affected by a gene therapy trial. Sponsors who understand that a dual structure arrives at submission in a stronger position than those who treat the IBC as an afterthought.
Use the IRB & IBC as Early Resources
The most common and costly mistake sponsors make is waiting until protocol development is complete and all documents have been finalized (and perhaps already submitted elsewhere) to start interacting with the IRB and IBC. Protocols that arrive with structural problems, missing safety plans, or pediatric regulatory issues that were never surfaced earlier do not get approved quickly. They generate revision requests and timeline delays and, in some cases, require significant redesign. In gene therapy for genetic diseases, every month lost to a preventable revision is a month patients cannot get back.
No sponsor wants to file a protocol amendment before a study has enrolled a single patient. Early consultation with an experienced IRB and IBC can surface the kinds of issues that lead to those amendments. It is substantially easier to revise a protocol before submission than after. For sponsors in this space, early engagement with the IRB and IBC can be the difference between a program that moves and one that stalls.
What does useful early engagement look like in practice? Come with a plan that the IRB can react to. That means knowing your intended population, having a preliminary sense of your oversight structure, and understanding the regulatory framework that applies to your patient population. For IBC engagement specifically, sponsors benefit from reviewing the IBC application in advance to understand what information will be required and to prepare accordingly. A conversation with an IRB or IBC that knows this space is one of the most efficient investments a sponsor can make in a program’s development timeline.
Early Stages, High Stakes
Gene therapy for genetic diseases is still in its early stages, and the opportunity for sponsors is real. The science is advancing, the regulatory framework is maturing, and the path from promising research to safely executed trial is becoming better understood. The sponsors who get there are the ones who treat IRB and IBC engagement as part of building that path, not as a hurdle at the end.
For the patients waiting on these therapies, a program built on the right foundation is no small matter. It may be the only chance they get.
About the Authors:
Raffaella Hart, MS, CIP, serves as Senior Vice President at BRANY, where she leads the organization’s IRB, IBC, and Quality Assurance services. A Certified IRB Professional (CIP) with over 25 years of experience in IBC and IRB administration, she was instrumental in achieving and maintaining BRANY IRB’s full AAHRPP accreditation. Hart holds a Master of Science in Healthcare Science with a focus in Clinical Research Administration from The George Washington University and a B.S. in Psychobiology from Binghamton University. Her work has been featured in IRB Advisor, Clinical Trials, The CenterWatch Monthly, The Monitor, and Seminars in Nuclear Medicine.
Vanessa Rodriguez is BRANY’s IRB/IBC Supervisor. Ms. Rodriguez joined the BRANY team in 2009. Her ability to learn, navigate, and apply the regulations relevant to both IRB and IBC has led to several promotions at BRANY, including her most recent promotion to IRB/IBC Supervisor. Ms. Rodriguez is extremely knowledgeable in her role as BRANY’s IBC administrator. Vanessa continuously educates herself on the NIH Guidelines related to research involving human gene transfer or use of recombinant or synthetic nucleic acid molecules by attending conferences, speaking with liaisons at the Office of Science Policy, and meeting with IBC committee members and biosafety officers, in addition to her own research on these topics. Ms. Rodriguez has over 15 years of experience in research administration, including IBC administration, and is a Certified IRB Professional (CIP).
